+ 3.14
+ 0.9%
+ 2.31
+ 0.68%
+ 2.37
+ 0.56%
+ 0.38
+ 0.27%
+ 0.28
+ 0.17%

Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says

February 28, 2018 2:48 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced Tuesday that the U.S. Food and Drug Administration accepted a New Drug Application for eravacycline, an antibiotic for complicated intra-abdominal infection, for priority review.

Traders initially reacted positively, and so did analysts.

The Rating

B Riley analyst Madhu Kumar reiterated a Buy rating on the stock with a $6 price target.

The Thesis

The NDA news is supportive of expectations for U.S. regulatory approval in the third quarter.

“We consider eravacycline receiving priority review a key positive, as the FDA gives this accelerated review process to drugs with the potential for ‘significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to standard applications,’” the analyst said in a Tuesday note. 

That acknowledged superiority would position Tetraphase to seize market share.

Eravacycline posted successful results in both the IGNITE1 and IGNITE4 Phase 3 trials, and although it failed in IGNITE3 for complicated urinary tract infection, Kumar does not expect negative read across to the intra-abdominal infection prospects.

Price Action

Tetraphase shares were trading up 6.44 percent at $2.81. 

Related Links:

The Companies That Led 2017's Biotech Rally

Pharma M&A Picks Up Momentum

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Related Articles

Tetraphase Pharma Shares Plunge After Antibiotic Fails Late-Stage Trial

Is Tetraphase Pharmaceuticals A Buyout Candidate? Brean Capital Thinks So

Bidding War Sends Tetraphase Shares Soaring

Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged. read more

Vetr Crowd Downgrades Tetraphase